The cost of treating systemic fungal infections.
The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have been difficult to estimate because of the lack of information on the costs of systemic fungal infections. Fluconazole is effective in prophylaxis and represents a direct cost saving compared with polyenes. However, itraconazole oral solution, an effective and widely used antifungal prophylactic agent, has not been analysed for cost effectiveness. In empirical therapy, the development of new formulations of existing agents has prompted a number of cost comparisons. In particular, the cost of treatment with conventional amphotericin-B has been compared with the costs of the new lipid-associated formulations of amphotericin-B or the new intravenous (IV) formulation of itraconazole. The acquisition costs of lipid-associated amphotericin-B and IV itraconazole are higher than the cost of conventional amphotericin-B; however, these costs appear to be offset by reductions with both these agents in the cost for increased length of hospital stay and treating adverse events seen with conventional amphotericin-B. In neutropenic patients and bone marrow transplant recipients, IV itraconazole may be the most cost-effective option for empirical therapy.
van Gool
R
R
Janssen Research Foundation, Beerse, Belgium. RVGOOL@janbe.jnj.com
D017088:AIDS-Related Opportunistic Infections / Q000191:economics*; D000935:Antifungal Agents / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D006801:Humans; D009181:Mycoses / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control
D000935:Antifungal Agents